Key result
Aliskiren exposure was greater than proportional over the 75-600 mg dose range, with a proportionality coefficient for AUC(0-infiniti) of 1.18 (90% CI 1.10-1.25).
Why the study?
Does aliskiren exhibit dose-proportional pharmacokinetics over the range of 75-600 mg in healthy subjects?
RCT (n=32)
Open-label
randomized
No
Does aliskiren exhibit dose-proportional pharmacokinetics over the range of 75-600 mg in healthy subjects?
Effect estimate: beta 1.18 (95% CI 1.10-1.25)
Aliskiren exhibits greater than dose-proportional pharmacokinetics over the 75-600 mg range, with a 2.3- and 2.6-fold increase in AUC and Cmax over the clinical 150-300 mg range.
May inform aliskiren dosing to limit overexposure; extends nonlinear PK characterization for modeling.
OBJECTIVE: To evaluate the dose-proportionality of the pharmacokinetics of aliskiren, the first in a new class of orally active direct renin inhibitors approved for the treatment of hypertension. METHODS: This was an open-label, single-center, single-dose, randomized, 4-period crossover study. Following a 21-day screening period, 32 healthy male or female subjects (ages 18 - 45 years) were randomized to 1 of 4 aliskiren dosing sequence groups (8 subjects per group): 75, 150, 300 and 600 mg. Blood samples were obtained for determination of plasma aliskiren concentrations (HPLC/MS/MS) for 96 h post dose. Log-transformed pharmacokinetic parameters AUC and C(max) were analyzed to determine dose-proportionality using the power model, parameter = A*(Dose)(beta), where A = intercept and beta = dose-proportionality coefficient. The predefined dose-proportionality criteria over the dose range 75 â 600 mg were 90% confidence intervals (CI) for beta contained within the range 0.89 - 1.11. RESULTS: AUC and Cmax values increased with increasing doses of aliskiren. Both AUC and C(max) were associated with high variability (coefficient of variation 55 - 64% for AUC and 59 - 117% for C(max)). The estimated proportionality coefficients (beta) for AUC(0-infiniti), AUC(0-t) and C(max) were 1.18 (90% CI 1.10, 1.25), 1.29 (90% CI 1.22, 1.36) and 1.42 (90% CI 1.31, 1.52), respectively. Dose-proportionality was, therefore, not demonstrated across the entire 8-fold dose range. For the clinical dose range of 150 â 300 mg, increases of 2.3- and 2.6-fold were observed for AUC and C(max), respectively. All doses of aliskiren were well tolerated. CONCLUSIONS: Exposure to aliskiren was greater than proportional over the dose range of 75 - 600 mg. Over the therapeutic dose range of 150 â 300 mg approved for the treatment of hypertension, AUC and Cmax increased by 2.3- and 2.6-fold, respectively. The pharmacokinetics of aliskiren show relatively high intersubject variability.
No takes yet. Share an insight, caveat, or question.
Limoges et al. (2008) conducted an RCT in healthy subjects (n=32). aliskiren was evaluated on dose-proportionality coefficient (beta) for AUC(0-infiniti) (beta 1.18, 95% CI 1.10-1.25). Aliskiren exposure was greater than proportional over the 75-600 mg dose range, with a proportionality coefficient for AUC(0-infiniti) of 1.18 (90% CI 1.10-1.25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: